We are advancing the scientific understanding of I-O
through our extensive portfolio of investigational compounds and approved agents.
therapies provide a novel way to treat cancer by using drugs to assist the body's immune system.
BEA's fully integrated industry economic accounts provide an ideal framework for preparing satellite accounts because they encompass both the I-O
accounts (including final demand) as well as GDP by industry accounts.
"We're pleased to reach this agreement with I-O
Data," said David Kaefer, general manager of Intellectual Property Licensing at Microsoft.
The company said that the patent covenants which are affected relate to I-O
Data's network-attached storage devices and its routers, which run Linux.
This release marked the introduction of a new estimating methodology that eliminated the inconsistency in the two measures of industry value added, improved the accuracy of both accounts, and accelerated the availability of the annual I-O
The II-ON gives us the chance to work more efficiently and collaboratively with Bristol-Myers Squibb and the other II-ON academic centers to address scientific questions in I-O
, said Roy Herbst, M.D., Ph.D., director of the Center of Immuno-Oncology at Yale Cancer Center and Yales principal investigator of the II-ON team.
According to the I-O
RPM research program, BMS and several academic-based cancer centres will investigate immuno-oncology therapeutics as potential treatment options for patients with high-risk and poor prognostic cancers, described as a rare population malignancy.
The up-to-date and completely integrated I-O
tables are a crucial new tool for businesses, policy analysts, economists, and others who want to drill deep into BEA's detailed data.
QIAGEN and Bristol-Myers Squibb intend to develop GEPs for several Bristol-Myers Squibb I-O
molecules under the initial agreement.
The centerpiece of this revision was the integration of the annual I-O
accounts with the GDP by industry accounts.
Our vision for the future of cancer care is focused on researching and developing transformational Immuno-Oncology (I-O
) medicines that will raise survival expectations in hard-to-treat cancers and will change the way patients live with cancer.